Background

 ●While EGFR-mutant NSCLC tumors generally are resistant to PD-1/PD-L1 inhibitors, a small subset of patients can have durable responses.1,2

●EGFR tumors demonstrate significant molecular heterogeneity, especially with respect to mutation subtypes.

●A small number of studies suggest better outcomes with checkpoint inhibitors in patients with tumors possessing uncommon EGFR mutations3or L858R mutations,1however data on this are still limited.

●There is a lack of clarity on the genomic and immune profiles of EGFR mutation subtypes, and further elucidation of this may help optimally identifying patients likely to respond to immune-based therapies.